Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down – Here’s Why

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $15.55, but opened at $13.80. Y-mAbs Therapeutics shares last traded at $14.60, with a volume of 78,421 shares trading hands.

Wall Street Analyst Weigh In

YMAB has been the subject of several research analyst reports. Canaccord Genuity Group upgraded shares of Y-mAbs Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 13th. Morgan Stanley dropped their target price on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a research report on Tuesday, August 13th. BMO Capital Markets dropped their target price on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a research report on Tuesday, August 13th. HC Wainwright reiterated a “buy” rating and set a $22.00 target price on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $26.00 target price on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $21.14.

Y-mAbs Therapeutics Trading Down 2.9 %

The stock has a market capitalization of $673.01 million, a P/E ratio of -22.70 and a beta of 0.68. The stock’s fifty day moving average price is $14.08 and its two-hundred day moving average price is $13.17.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.44%. The business had revenue of $22.80 million during the quarter, compared to the consensus estimate of $23.09 million. During the same quarter in the previous year, the firm posted ($0.14) earnings per share. As a group, analysts expect that Y-mAbs Therapeutics, Inc. will post -0.62 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 30,000 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $12.97, for a total transaction of $389,100.00. Following the transaction, the insider now directly owns 67,681 shares of the company’s stock, valued at approximately $877,822.57. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Thomas Gad sold 30,000 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $12.97, for a total value of $389,100.00. Following the sale, the insider now directly owns 67,681 shares of the company’s stock, valued at $877,822.57. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Joris Wilms sold 5,000 shares of the company’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $14.69, for a total transaction of $73,450.00. Following the completion of the sale, the chief operating officer now directly owns 30,600 shares in the company, valued at $449,514. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 100,000 shares of company stock valued at $1,338,100 over the last three months. 22.50% of the stock is owned by company insiders.

Institutional Trading of Y-mAbs Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Squarepoint Ops LLC boosted its stake in Y-mAbs Therapeutics by 143.4% in the 2nd quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock worth $1,527,000 after purchasing an additional 74,452 shares in the last quarter. Millennium Management LLC boosted its stake in Y-mAbs Therapeutics by 23.8% in the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock worth $4,225,000 after purchasing an additional 67,233 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Y-mAbs Therapeutics by 15.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock worth $5,853,000 after purchasing an additional 65,732 shares in the last quarter. Boston Partners bought a new position in Y-mAbs Therapeutics in the 1st quarter worth about $556,000. Finally, XTX Topco Ltd bought a new position in Y-mAbs Therapeutics in the 2nd quarter worth about $297,000. 70.85% of the stock is owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.